Debt - Liability for Sale of Future Royalties (Details) - USD ($) $ in Thousands	12 Months Ended
Dec. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Beginning balance	$ 1,814,097
Less: Non-cash royalty revenue payable to Royalty Pharma	(181,507)
Plus: non-cash interest expense recognized	207,394
Plus: Cash received from Royalty Pharma	241,792	$ 1,000,000
Ending balance	$ 2,081,776	$ 1,814,097
Effective interest rate of the liability component	9.80%

Amount of liabilities related to the sale of future royalties.

No definition available.

Name:	ptct_LiabilitySaleOfFutureRoyalties
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of interest expense recognized related to the liability for the sale of future royalties per terms of the agreement.

+ References

No definition available.

+ Details

Name:	ptct_LiabilitySaleOfFutureRoyaltiesInterestExpense
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of royalty revenue recognized during the period relating to the sale of future royalties payable under terms of the agreement.

+ References

No definition available.

+ Details

Name:	ptct_LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received for sale of future royalties during the current period.

+ References

No definition available.

+ Details

Name:	ptct_ProceedsFromSaleOfFutureRoyalties
Namespace Prefix:	ptct_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

+ Details

Name:	us-gaap_DebtDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details

Name:	us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant